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Background: Lifelong antiretroviral therapy (ART) for pregnant
and breastfeeding women (Option B+) was rolled out in Zimbabwe
from 2014, with simultaneous raising of the CD4 treatment threshold
to 500 cells per cubic millimeter in nonpregnant/breastfeeding adults
and children 5 years and over.
Methods: Lablite is an implementation project in Zimbabwe, Malawi,
and Uganda evaluating ART rollout. Routine patient-level data were
collected for 6 months before and 12 months after Option B+ rollout at
a district hospital and 3 primary care facilities in Zimbabwe (2 with
outreach ART and 1 with no ART provision before Option B+).
Results: Between September 2013 and February 2015, there were
1686 ART initiations in the 4 facilities: 91% adults and 9% children
younger than 15 years. In the 3 facilities with established ART,
initiations rose from 300 during 6 months before Option B+ to 869
(2.9-fold) and 463 (1.5-fold), respectively, 0–6 months and 6–12
months after Option B+. Post-Option B+, an estimated 43% of
pregnant/breastfeeding women needed ART for their own health,
based on World Health Organization stage 3/4 or CD4 #350 per
cubic millimeter (64% for CD4#500). Seventy-four men (22%) and
123 nonpregnant/breastfeeding women (34%) initiated ART with
CD4 .350 after the CD4 threshold increase. Estimated 12-month
retention on ART was 79% (69%–87%) in Option B+ women
(signiﬁcantly lower in younger women, P = 0.01) versus 93% (91%–
95%) in other adults (difference P , 0.001).
Conclusions: There were increased ART initiations in all patient
groups after implementation of World Health Organization 2013
guidelines. Retention of Option B+ women was poorer than retention
of other adults; younger women require attention because they are
more likely to disengage from care.
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INTRODUCTION
World Health Organization (WHO) 2013 guidelines
promoted expanded eligibility for antiretroviral therapy
(ART) by raising the CD4 threshold for treatment initiation
from 350 to 500 cells per cubic millimeter for HIV-infected
individuals aged 5 years and older. ART was recommended
for all children younger than 5 years. Option B (ART during
pregnancy and breastfeeding) or Option B+ (provision of
ART for life for pregnant/breastfeeding women) for high
fertility/high HIV prevalence countries was recommended
over Option A (ART perinatally only) for prevention of
mother-to-child transmission (PMTCT).1 The PROMISE trial
subsequently conﬁrmed superiority of Option B over Option
A for reducing mother-to-child transmission (MTCT).2
Malawi was the ﬁrst country to implement “Option B+” in
September 2011.3 By 2015, most low-/middle-income coun-
tries were piloting, rolling out, or implementing Option B+.4
Advantages of Option B+ over previous PMTCT Option A
and Option B (ART during pregnancy and breastfeeding)
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include: simpliﬁcation of PMTCT program requirements
(notably no requirement for a CD4 count result to be returned
before ART initiation); extended protection from MTCT in
future pregnancies from conception; prevention against
sexual transmission to serodiscordant partners; beneﬁt to the
woman’s health of earlier treatment and avoiding the risks of
stopping and starting ART; and a simple message to
communities that once ART is started, it is taken for life.5
Striking increases in pregnant women accessing ART
have been seen in countries implementing Option B+,
although the ﬁrst countries to implement Option B+ tended
to have low PMTCT coverage.6,7 Because Option B+ is
relatively new, there are few reports of outcomes from
national programs. In the ﬁrst national cohort of Option B+,
women in Malawi retention at 12 months, when most African
women are still breastfeeding, was only 77%7; retention
within more recent cohorts is similar,8 emphasizing the need
for support measures for this population. At Elizabeth Glazer
Pediatric AIDS Foundation sites in Uganda, early 6-month
data suggest slightly higher retention.6
Zimbabwe adopted Option B+ after a National Stake-
holder Consultation in 20139 and began piloting in July 2013
with rollout in 2014. National guidelines issued at the end of
2013 also included recommendations to treat all HIV-infected
children younger than 5 years and to treat older children and
adults with WHO stage 1/2 disease and CD4 count ,500.10
Before the introduction of Option B+, the PMTCT program
(providing Option A) in Zimbabwe was functioning compar-
atively well (78% ART coverage in pregnant women in
201311), population HIV and CD4 testing levels were high,
and ART coverage was also high at 77% in treatment-eligible
adults in 201312), although considerably lower in children at
46%.12 However, ART clients were frequently traveling long
distances to access treatment, and ART provision in primary
care (where available) was principally through outreach teams
visiting from local hospitals. Implementation of Option B+
necessitated integration of ART into all PMTCT settings where
services are mostly delivered by nurses at the primary health
facility level; for Zimbabwe, this required expanding the ART
program from 1006 to 1560 facilities between 2013 and 2015.9
The Lablite Project13 worked with Ministries of Health
in Malawi, Uganda, and Zimbabwe to evaluate rollout of ART
at 4 nonresearch sites (each comprising a district hospital and
2–4 linked rural primary care facilities). In Zimbabwe, Lablite
was present in Zvimba, a rural district west of Harare, with
270,000 inhabitants and estimated HIV prevalence of 14%.
The district includes 2 secondary care facilities and 31 primary
care facilities. Here, we report on ART provision during
6 months before implementation of Option B+ (March 2014)
and 12 months after implementation, in 1 of the district
hospitals and 3 primary care facilities. The CD4 threshold for
starting ART was raised from 350 to 500 cells per cubic
millimeter in January 2014, 2 months earlier than implemen-
tation of Option B+; but in practice, few initiations at higher
CD4s occurred before Option B+ was rolled out. Aims of this
article were to describe the impact of Option B+ provision and
the increase in CD4 initiation threshold on ART provision and
to quantify retention on ART, identifying predictors of high
retention in care.
METHODS
The Lablite facilities were selected in consultation
with Ministry of Health and Child Welfare (MOHCW). A
“hub-spoke” approach was taken, with Banket District
Hospital being the hub for 3 primary care facilities; before
the Lablite project, 2 facilities (Nyabira, Mutorashanga) were
beneﬁting from ART provision by Banket District Hospital
outreach teams fortnightly and 1 facility (Zowa) had no ART
provision. In collaboration with MOHCW, health care
workers were trained and mentored on site using national
training materials, supplemented by a checklist for monitoring
patients on ART and a handbook. Staff at Banket District
Hospital were trained ﬁrst and they mentored staff in the
primary care facilities. The primary care facilities then
received accreditation as ART-initiating and follow-up sites.
Routine individual patient-level data were collected
regularly from ART registers, appointment registers, and
facility patient cards for all patients newly registered on ART
between September 2013 and February 2015 by a data
capturer independent from clinic staff. Registrations include
patients who are initiating ART and patients described as
“transfers-in” who have started ART at another health care
facility and are moving facility for follow-up on ART (during
this study, often because of primary care facilities now
providing full ART services, when they had not previously).
Defaulters (no visit for 90 days) were cross-checked with
clinic defaulter lists (lists that the nurses are required to keep
within each clinic to identify defaulters for MOHCW
reporting). Data were entered in bespoke database tools that
mimicked the clinic paper-based tools.
Reasons for starting ART were coded for analysis in
a hierarchical manner as follows: children younger than 15
years, adults with WHO stage 3/4 disease (including
tuberculosis), pregnant post-Option B+, breastfeeding post-
Option B+, CD4,threshold. Pregnancy and breastfeeding
were coded as reasons for initiation above CD4 for 2 reasons:
(1) Option B+ women started ART immediately without
waiting for CD4 results and (2) not all pregnant/breastfeeding
women have CD4 results. Current outcome at last data
collection (between March and June 2015) was used to
estimate retention on ART at the end of follow-up (February
28, 2015), gaps in care before last data collection were
ignored. Patients who transferred out to a new health facility
were censored at the date of transfer.
Comparisons of initiation characteristics were planned
between 6-month periods, pre-Option B+, and 0–6 and 7–12
months post-Option B+. Retention in care was estimated
separately for new ART initiations and patients who trans-
ferred in on ART. Comparisons of retention on ART were
planned between facilities and for new ART initiations
between Option B+ women and other adults. Proportions
were compared using x2 tests. Rank sum tests were used to
compare distributions of continuous variables. Retention in
care at 6 and 12 months was estimated by the Kaplan–Meier
survivor function. Hazard ratios (HRs) were estimated using
Cox regression; HRs and P-values presented in the text to
assess differences in retention by patient-level characteristics
and facility are from univariable models (log-rank tests gave
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similar P-values, data not shown). Multivariable Cox models
were selected by backward selection with signiﬁcance level of
0.1; continuous variables were included as fractional poly-
nomials. In patients who started ART for WHO stage 3/4
disease or CD4,threshold, we ﬁtted separate models for the
risks of death and default, including all the predictors
identiﬁed for the combined endpoint (cause-speciﬁc HRs
are presented). Cumulative incidence of death and default
were estimated using a competing risks framework.14 STATA
version 13.1 was used.
Role of the Funding Source
The study was funded by Department for International
Development, United Kingdom, who had no role in study
design, collection, analysis and interpretation of data, the
writing of the paper, or the decision to submit for publication.
The corresponding author had full access to all the data.
RESULTS
Between September 2013 and February 2015, there
were 2088 ART registrations across the 4 facilities, including
1686 (81%) new ART initiations and 402 (19%) patients
already on ART who transferred in from an alternative health
facility; 702 (42%) new initiations and 277 (69%) transfers-in
were at the primary care facilities.
In the 3 facilities with established ART provision
before Option B+ implementation, there were 300 ART
initiations in the 6 months before Option B+ rollout compared
to 869 and 463 initiations in the 0–6 months and 6–12 months
afterward, respectively, corresponding to 2.9- and 1.5-fold
increases, with the largest in the ﬁrst quarter (Table 1 and
Fig. 1). Initiations in children younger than 15 years
comprised 36 (12%), 60 (7%), and 43 (9%) of ART initiations
in the same 3 respective periods. Infants 2 years and younger
were in the minority and were seen primarily at the hospital;
37 of 92 (40%) children were 2 years and younger at the
hospital compared with 3 of 47 (6%) at primary care facilities
(P , 0.001). Throughout follow-up, adult males initiating
ART were older (P , 0.001) and had lower pre-ART CD4s
than nonpregnant/breastfeeding females (P , 0.001)
(Table 1). From March 2014, the median (interquartile range)
pre-ART CD4 rose from 143 (71–243) to 216 (104–326) in
men (P , 0.001) and from 192 (89–263) to 279 (161–396) in
nonpregnant/breastfeeding women (P , 0.001). However,
even between March 2014 and February 2015, 79 of 329
(24%) men and 47 of 362 (13%) nonpregnant/breastfeeding
women had pre-ART CD4 #100 cells per cubic millimeter.
There were 3 ART initiations in men at the hospital where
reason given for initiation was “male partner of an Option B+
female”; although all were WHO stage 1, CD4s at initiation
were 66, 313 and 470 cells per cubic millimeter, so they were
eligible for treatment for their own health.
Over the 6 months before rollout of Option B+, 34
(24%) women initiating ART were pregnant/breastfeeding,
including 3 early Option B+ initiations at the hospital;
excluding these 3 and 1 woman who was not WHO staged,
21 of 30 (70%) had WHO stage 3/4 disease. In contrast, in the
ﬁrst quarter after Option B+ rollout, initiations rose to 269
among pregnant/breastfeeding women (corresponding to
a 16-fold increase) and then reduced to 82, 42, and 42 in
the subsequent 3 quarters (a 6-fold increase over the ﬁrst year
after Option B+). After Option B+, 59 of 435 (13%) pregnant/
breastfeeding women were WHO stage 3 at ART initiation
and none had stage 4 disease. CD4 data were incomplete
[only 190 of 376 (51%) with WHO stage 1/2 had a CD4
recorded]; 64 (34%) stage 1/2 women had #350 cells per
cubic millimeter and 47 (25%) had 351–500 cells per cubic
millimeter, implying that overall, 43% of pregnant/breast-
feeding women would have been eligible for treatment of
their own health based on WHO 2010 disease progression
criteria (WHO stage 3/4 or CD4 #350 cells per cubic
millimeter) or 64% based on WHO 2013 criteria (WHO
stage 3/4 or CD4 #500 cells per cubic millimeter). Median
age at ART initiation in pregnant/breastfeeding women was
similar pre- and post-Option B+ (Table 1); but the proportion
of adolescents younger than 20 years increased from 1 (3%)
before Option B+ to 25 (7%) in the ﬁrst 6 months and 13
(15%) in the second 6 months post-Option B+ (trend
P = 0.008).
In Zowa, a primary care facility, where ART provision
was started later and alongside Option B+ rollout (from April
2014), there were 54 ART initiations, including 6 in children
younger than 15 years (Fig. 1).
Median follow-up in individuals newly initiating ART
was 8 (3–11) months. Retention on ART in 1140 adults who
started ART for disease progression (all patients pre-Option
B+ implementation; pregnant/breastfeeding women with
WHO stage 3/4 disease, and nonpregnant/breastfeeding
patients post-Option B+ implementation) was 95% (95%
conﬁdence interval: 93% to 96%) at 6 months, including 12
deaths and 39 losses to follow-up (LTFU); 12-month
retention was 93% (91%–95%) (18 deaths, 40 LTFU). Figure
2A shows the cumulative incidence of death and default
across all sites. Retention varied between sites (Table 2; P ,
0.001); 12-month retention in the primary care facilities was
86% (80%–90%) compared with 98% (96%–99%) at the
hospital. There was no evidence that retention-in-care was
worse when ART was initiated after Option B+ had rolled out
compared with before Option B+ (Table 2). Retention was
higher in patients with higher CD4 and lower in pregnant/
breastfeeding patients (pre-Option B+ or also WHO stage
3/4); when we looked at the risks of death and LTFU
separately, the CD4 effect was predominantly because of an
increased risk of death in patients with low CD4, whereas
pregnancy/breastfeeding predicted higher LTFU but not
higher mortality (Table 3). Among WHO stage 1/2 patients,
those with CD4 .350 had similar retention to those with
CD4 #350 [HR: 1.11 (0.63–1.94)].
Retention on ART in 386 women who newly started
ART for Option B+ was 85% (81%–88%) at 6 months
(1 death, 53 LTFU) and 79% (69%–87%) at 12 months
(3 deaths, 55 LTFU); this was signiﬁcantly lower than retention
in the adults starting ART for WHO 3/4 or CD4,threshold
[across all periods: HR 3.09 (2.15–4.46), P , 0.001;
restricted to March 2014 onward: HR 4.00 (2.59–6.09),
P , 0.001]. Retention differed markedly by age at initiation,
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TABLE 1. Characteristics at ART Initiation in a District Hospital and 2 Primary Care Facilities With Established ART Provision Before
Option B+ Implementation*
Pre-Option B+ 0–6 mo Post-Option B+ 7–12 mo Post-Option B+
TotalSeptember 2013 to February 2014 March 2014 to August 2014 September 2014 to February 2015
Median
(IQR) N
% of Total
or of
Subgroup
Median
(IQR) N
% of Total
or of
Subgroup
Median
(IQR) N
% of Total
or of
Subgroup N
% of Total
or of
Subgroup
Total† 300 869 463 1632
Children 36 12 60 7 43 9 139 9
Age, yrs 4 (2–9) 5 (2–11) 6 (2–8)
#2 10 28 16 27 14 33 40 29
3–14 26 72 44 73 29 67 99 71
Adult males 112 38 227 26 156 34 495 31
Age, yrs 38 (33–45) 37 (32–43) 37 (32–43)
WHO stage
Stage 1/2 19 17 68 30 35 22 122 25
Stage 3 90 81 159 70 121 78 370 75
Stage 4 2 2 0 0 0 0 2 0.4
CD4‡ 143 (71–243) 215 (103–341) 216 (112–321)
#100 29 36 46 25 33 23 108 26
101–200 27 34 38 20 31 22 96 23
201–350 22 28 59 32 48 34 129 32
351–500 2 3 38 20 28 20 68 17
.500 0 0 5 3 3 2 8 2
Nonpregnant and
nonbreastfeeding
adult females
110 38 224 26 180 39 514 32
Age, yrs 35 (29–42) 34 (30–40) 34 (28–42)
WHO stage
Stage 1/2 20 18 66 29 46 26 132 26
Stage 3 88 81 157 70 132 73 377 73
Stage 4 1 1 1 0.5 2 1 4 1
CD4§ 192 (89–263) 295 (172–398) 266 (152–395)
#100 24 28 20 10 27 16 71 16
101–200 21 24 43 22 41 24 105 23
201–350 38 44 63 33 45 26 146 33
351–500 4 5 62 32 54 32 120 27
.500 0 0 4 2 3 2 7 2
Pregnant or
breastfeeding adult
females
34 12 351 41 84 18 469 29
Age, yrs 28 (26–31) 29 (24–33) 26 (21–32)
Pregnant 18 53 182 52 57 68 257 55
WHO stage
Stage 1/2 12 36 305 87 71 85 388 83
Stage 3 20 61 46 13 13 16 79 17
Stage 4 1 3 0 0 0 0 1 0.2
CD4k 250 (148–307) 454 (304–613) 339 (245–501)
#100 5 18 12 7 3 8 20 8
101–200 6 21 16 9 4 11 26 11
201–350 17 61 29 19 12 32 58 24
351–500 0 0 44 26 8 22 52 22
.500 0 0 71 41 10 27 81 34
*Zowa primary care health facility is not included as there was no ART provision before Option B+, hence its inclusion post-Option B+ could distort comparisons.
†15 individuals with missing age excluded from sub-groups below.
‡CD4 at initiation was available in 80 (71%), 186 (82%), 143 (92%) males by period.
§CD4 at initiation was available in 87 (79%), 192 (86%), 167 (93%) nonpregnant and nonbreastfeeding females by period.
kCD4 at initiation was available in 28 (82%), 172 (49%), 37 (44%) pregnant or breastfeeding females by period.
IQR, interquartile range.
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being lower in younger women (Table 2 and Fig. 2B).
Retention did not differ by pre-ART CD4 (Table 2). Although
32 women were LTFU by 1 month, 20 of 32 attended 1 post-
ART initiation visit (median 14 days after starting ART).
Importantly, in the subgroup of women who started ART
during pregnancy/breastfeeding with WHO stage 3/4 or CD4
#350, there was no evidence for worse retention after Option
B+ implementation than before [HR: 0.78 (0.28–2.16)].
Among 145 children younger than 15 years at ART
initiation, there were 3 (2%) deaths, 16 (11%) LTFU, and 10
(7%) transfers-out. The 3 children who died were all seen at
the hospital; two 3-year-olds died very soon after starting
ART (13 days; 45 days) and one 2-year-old died 12 months
after initiation. At 6 months, retention on ART was 87%
(80%–92%) and at 12 months it was 85% (77%–91%). We
found no evidence that retention at 12 months in the primary
care facilities [94% (83%–98%)] was worse than at the
hospital [79% (67%–88%)].
Retention on ART in the 402 individuals who trans-
ferred into one of the facilities already on ART was 95%
(92%–97%) 6 months after transfer (0 death, 18 LTFU) and
94% (90%–96%) (0 death, 20 LTFU) at 12 months. Over half
the individuals LTFU (11/20) did not return after their ﬁrst
registration visit.
FIGURE 1. A–D, Number of new ART
initiations by patient status at ART
initiation, period and health facility
(PC, primary care facility).
FIGURE 2. A and B, Cumulative
incidence of death or default (LTFU)
by time since ART initiation. *Option
B+ women defined as women start-
ing ART after Option B+ provision,
who were WHO stage 1 or 2 and
pregnant or breastfeeding.
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DISCUSSION
The last 5 years have seen rapid changes in both
PMTCT guidance and practice and CD4 threshold recom-
mendations for ART initiation. The Lablite project13 was
working with Ministries of Health in Malawi, Zimbabwe, and
Uganda between 2011 and 2015 and collating routine data on
ART rollout in nonresearch facilities in rural areas. In
Zimbabwe, this provided an important opportunity to com-
pare ART initiations and retention on ART before and after
introduction of Option B+ and the increase in CD4 threshold.
We found that after Option B+ implementation and the
increased CD4 threshold, greater numbers of all patients
started ART, including children. Patients who started ART at
CD4 .350 or for Option B+ (with high CD4) inevitably did
so as a result of guideline changes; however, increases in
other patient groups may have occurred anyway. Devolve-
ment of ART care to the primary care staff with support from
MOHCW allowed management of increasing patient num-
bers. However, drug supply remains a concern; although no
stock-outs of ART were reported, there were anecdotal
reports of patients having to return to clinic in between
scheduled visits to collect ART because of low supplies, and
stock-outs of cotrimoxazole did occur.
Overall mortality was low and retention in care was
extremely good in patients starting ART for disease pro-
gression (93% at 12 months), better than reported for the ART
program in Zimbabwe between 2007 and 201015 and in other
settings.16 Retention was higher at the hospital than in the
primary care facilities, possibly because of the Lablite model
of training whereby hub staff received additional training to
mentor staff at primary care facilities. Encouragingly, we
found no evidence that introduction of Option B+ had
a detrimental effect on retention of patients starting ART
for disease progression. Retention on ART was poorer in
Option B+ women than in other adults starting ART, as found
in Malawi,17 but similar to retention reported in other rural
TABLE 2. Predictors of Death and Loss to Follow-up From Care in Adults Newly Starting ART
Initiated for WHO Stage 3/4 or CD4,Threshold Initiated for Option B+
Univariable Analysis Multivariable Analysis* Univariable Analysis Multivariable Analysis*
N = 1140 (58 Failures)† N = 904 (41 Failures)‡ N = 386 (58 Failures)§ N = 386 (58 Failures)
HR (95% CI) P HR (96% CI) P HR (95% CI) P HR (95% CI) P
Site
Hospital 1.00 1.00 1.00
Nyabira (PC) 7.52 (3.85 to 14.7) 7.32 (2.96 to 18.1) 1.12 (0.60 to 2.09)
Mutorashanga (PC) 3.74 (1.90 to 7.36) 4.02 (1.72 to 9.41) 0.61 (0.29 to 1.28)
Zowa (PC) 1.38 (0.18 to 10.5) ,0.001 — ,0.001 — 0.33
Initiation period
September 2013 to
February 2014
1.00 1.00 —
March 2014 to
February 2015
0.51 (0.30 to 0.87) 0.01 0.42 (0.21 to 0.86) 0.02 —
Sex
Male 1.00 —
Female 0.92 (0.55 to 1.55) 0.77 —
Age at initiation
(per year increase)
0.97 (0.95 to 1.00) 0.07 0.94 (0.90 to 0.98) 0.01 0.94 (0.90 to 0.98) 0.01
WHO stage at initiation
Stage 1/2 1.00 1.00 —
Stage 3 0.55 (0.32 to 0.95) 0.56 (0.27 to 1.18) —
Stage 4 4.35 (1.02 to 18.6) 0.004 4.95 (0.99 to 24.7) 0.01 —
CD4 at initiation
(per 10 cells/mm3 increase)
0.97 (0.95 to 1.00) 0.02k 0.97 (0.95 to 1.00) 0.03 1.00 (0.98 to 1.01) 0.67
Pregnant/breastfeeding
No/male 1.00 1.00 —
Either pregnant or
breastfeeding
1.98 (0.97 to 4.04) 0.06 2.68 (0.99 to 7.25) 0.05 —
Pregnant — 1.00
Breastfeeding — 0.83 (0.49 to 1.41) 0.49
*All variables presented in the univariable analysis were considered for inclusion in the multivariable model. Continuous variables (CD4 and age) were included as fractional
polynomials for model selection, which was based on backward elimination (P , 0.10).
†Because of missing data, CD4 model (N = 944, failures = 41); WHO stage model (N = 1137, failures = 58).
‡Patients with missing CD4 or WHO stage or at Zowa (no pre-Option B+ data) were dropped in the ﬁnal model.
§Because of missing data, CD4 model (N = 193, failures = 28); because of no failures at Zowa, site model (N = 379, failures = 58).
kCD4 in the univariable model was better represented by CD420.5 but the linear term is shown here for comparability with the multivariable model and for ease of interpretation.
CI, conﬁdence interval; PC, primary care facility.
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districts of Zimbabwe (83%).18 At all 4 Lablite facilities,
women were asked to start ART immediately; for many, HIV
is a new diagnosis after routine testing during antenatal care,
and qualitative work suggests that immediate treatment may
be difﬁcult because of the limited time available to digest
a positive HIV diagnosis and understand and form decisions
around the uptake of a new lifelong treatment.17,19
CD4 counts were obtained for 85% of men and
nonpregnant/breastfeeding women before ART with no drop
in testing after Option B+ implementation or increase in CD4
threshold. Numbers of men and nonpregnant/breastfeeding
women starting ART with CD4 .350 were encouraging,
suggesting these individuals can be identiﬁed, although we
could not distinguish individuals newly diagnosed from those
already in pre-ART HIV care. Despite this, a signiﬁcant
proportion of individuals still start ART with low CD4s,
particularly men, who are more likely to present later than
women.20,21 Around half Option B+ women had a pre-ART
CD4 recorded; facilities were asked to continue providing
CD4s (unlike in Malawi where CD4s are not offered to
pregnant/breastfeeding women13); it is unclear whether re-
maining women had no CD4 measured or whether it was not
recorded. Assuming recorded CD4s were representative in
Option B+ women, importantly .40% pregnant/breastfeeding
women needed ART for their own disease (either WHO stage
3/4 or CD4 #350), consistent with other studies.22 It is
important that these women are retained on ART for their own
health and to prevent MTCT; health care workers may need
focused training to support retention of Option B+ women
with low CD4 counts.
Among Option B+ women, almost all attrition was
recorded as LTFU; unrecorded deaths are unlikely to be
a major contributor but we cannot distinguish between
women who have “silently” transferred to other health
facilities and those who have dropped out of care completely.
Age was a clear factor in predicting LTFU, with younger
women more likely to be lost. This corroborates ﬁndings in
Malawi23,24 and Zimbabwe.18 Targeted support measures are
needed for the increasing numbers of HIV-infected adolescent
and young pregnant women starting ART. We were only able
to look at retention on ART to 12 months, and it is important
to recognize that losses in this period, most of which were
very early, are likely to have been during pregnancy or
breastfeeding. In Malawi, it is estimated that half of those lost
in the ﬁrst 6 months may never have started ART.8 In
Zimbabwe, patients are asked to return to clinic 2 weeks after
starting ART, which is earlier than elsewhere (including
Malawi). We found that around 2/3 of women who were lost
by 1 month had returned for their 2-week visit; this raises
concerns that they took ART for only a short time and may
now have developed resistance as the half-life of efavirenz
may be much longer than other drugs. Data from Malawi
suggest that the risk of LTFU is much lower after the ﬁrst
year24; however, it will be some time before comparable data
are available for Zimbabwe.
In Zimbabwe since Option B+ rollout, policy has been
to encourage male partners to attend antenatal care with
pregnant women and to provide them with ART, irrespec-
tive of their own CD4 count. However, this seems to have
happened very rarely (only 3 men). Initiatives to engage
TABLE 3. Predictors of Death and Loss to Follow-up From Care in Adults Newly Starting ART for WHO Stage 3/4 or
CD4,Threshold
Death and Loss to Follow-up Loss to Follow-up Death
N = 904 (41 Failures)* N = 904 (28 Failures)† N = 904 (13 Failures)†
HR (96% CI) P cHR (95% CI) P cHR (95% CI) P
Site
Hospital 1.00 1.00 1.00
Nyabira (PC) 7.32 (2.96 to 18.1) 8.56 (3.00 to 24.4) 4.01 (0.23 to 70.4)
Mutorashanga (PC) 4.02 (1.72 to 9.41) 0.97 (0.25 to 3.71) 41.7 (4.63 to 376.1)
Zowa (PC) — ,0.001 — ,0.001 — 0.001
Initiation period
September 2013 to February 2014 1.00 1.00 1.00
March 2014 to February 2015 0.42 (0.21 to 0.86) 0.02 0.56 (0.23 to 1.36) 0.20 0.19 (0.04 to 0.96) 0.04
WHO stage at initiation
Stage 1/2 1.00 1.00 1.00
Stage 3 0.56 (0.27 to 1.18) 0.71 (0.28 to 1.79) 0.20 (0.04 to 1.04)
Stage 4 4.95 (0.99 to 24.7) 0.01 7.63 (0.79 to 74.1) 0.07 1.75 (0.17 to 17.7) 0.09
CD4 at initiation
(per 10 cells/mm3 increase)
0.97 (0.95 to 1.00) 0.03 0.99 (0.97 to 1.02) 0.54 0.90 (0.84 to 0.97) 0.003
Pregnant/breastfeeding
No/male 1.00 1.00 —
Either pregnant or breastfeeding 2.68 (0.99 to 7.25) 0.05 5.58 (1.82 to 17.1) 0.07 —‡ —
*Model selected in multivariable analysis for combined endpoint (death and LTFU), see Table 2.
†The full multivariable model was run for each competing event, censoring the alternative event.
‡There were no deaths among the pregnant and breastfeeding women.
PC, primary care facility; cHR, cause-speciﬁc HR.
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men are critical as lack of male involvement and the
complex dynamics between the women and their partners
including concerns about stigma are cited by health care
workers as a common reason for nonretention among
women on Option B+.25,26
Historically, HIV-infected children have been seen in
secondary and tertiary health care facilities in Zimbabwe,27 so
it was encouraging to see ART initiations in under 15’s at all
facilities, including the new primary care facility (where ART
provision was introduced alongside Option B+). However,
similar to other studies,28 children younger than 24 months
were treated almost exclusively at the hospital, suggesting
possible reluctance to test and treat infants in primary care.
Retention on ART was also somewhat lower in children than
in adults starting ART outside of Option B+. Previous studies
of retention in care of HIV-exposed and HIV-infected
children have identiﬁed a range of possible risk factors,
including characteristics of the carer for mortality and
LTFU29231; further research is needed to develop strategies
to mitigate losses.
After the START and TEMPRANO trials,32,33 WHO
released new guidelines recommending that all HIV-infected
individuals should start treatment as soon as possible after
a positive diagnosis.34 It is unclear how quickly this
recommendation will be taken up in sub-Saharan Africa.
Our early data on uptake of treatment in individuals with
CD4.350 after the rise in threshold suggest that there will be
demand. If adopted, lessons may be learned from Option B+
rollout; immediate treatment after provider-initiated testing in
“well” patients may not be dissimilar. In particular, adopting
treatment for all may facilitate retention of pregnant/breast-
feeding women by reducing the current disparity in access to
ART between women and their partners.
Strengths of the Lablite project include the study of
rural MOHCW facilities with little/no research experience
and use of routine data collected from paper records. This
contrasts with much of the existing Option B+ operations
research, which primarily focuses on larger health facilities
with electronic data capture. Additionally, we have data
before and after the introduction of Option B+ and changes in
WHO CD4 threshold guidelines and across all patient groups.
The primary weaknesses include lack of information on the
underlying causes of patients LTFU (common to most
studies) and use of a retrospective deﬁnition of LTFU (often
used in analysis of routinely collected data where visit data
may be incomplete). Our study is limited to 4 facilities and it
remains important to collate further data to determine how
generalizable our ﬁndings are.
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